9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Multicytokine-producing CD4 + T cells characterize the livers of patients with NASH

      research-article
      1 , 1 , 2 , 1 , 3 , 1 , 4 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 3 , 1 , 1 , 5 , 6 , 7 , 5 , 8 , 9 , 2 , 2 , 1 , 5 , 6 , 7 , 5 , 3 , 1 , 9 , 2 , 3 , 1 , 3 , 10 ,
      JCI Insight
      American Society for Clinical Investigation
      Hepatology, Immunology, Fibrosis, T cells

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          A role of CD4 + T cells during the progression from nonalcoholic fatty liver disease (NAFLD) to nonalcoholic steatohepatitis (NASH) has been suggested, but which polarization state of these cells characterizes this progression and the development of fibrosis remain unclear. In addition, a gut-liver axis has been suggested to play a role in NASH, but the role of CD4 + T cells in this axis has just begun to be investigated. Combining single-cell RNA sequencing and multiple-parameter flow cytometry, we provide the first cell atlas to our knowledge focused on liver-infiltrating CD4 + T cells in patients with NAFLD and NASH, showing that NASH is characterized by a population of multicytokine-producing CD4 + T cells. Among these cells, only those with a Th17 polarization state were enriched in patients with advanced fibrosis. In parallel, we observed that Bacteroides appeared to be enriched in the intestine of NASH patients and to correlate with the frequency of multicytokine-producing CD4 + T cells. In short, we deliver a CD4 + T cell atlas of NAFLD and NASH, providing the rationale to target CD4 + T cells with a Th17 polarization state to block fibrosis development. Finally, our data offer an early indication to test whether multicytokine-producing CD4 + T cells are part of the gut-liver axis characterizing NASH.

          Related collections

          Most cited references59

          • Record: found
          • Abstract: found
          • Article: not found

          DADA2: High resolution sample inference from Illumina amplicon data

          We present DADA2, a software package that models and corrects Illumina-sequenced amplicon errors. DADA2 infers sample sequences exactly, without coarse-graining into OTUs, and resolves differences of as little as one nucleotide. In several mock communities DADA2 identified more real variants and output fewer spurious sequences than other methods. We applied DADA2 to vaginal samples from a cohort of pregnant women, revealing a diversity of previously undetected Lactobacillus crispatus variants.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.

            Nonalcoholic fatty liver disease (NAFLD) is a major cause of liver disease worldwide. We estimated the global prevalence, incidence, progression, and outcomes of NAFLD and nonalcoholic steatohepatitis (NASH). PubMed/MEDLINE were searched from 1989 to 2015 for terms involving epidemiology and progression of NAFLD. Exclusions included selected groups (studies that exclusively enrolled morbidly obese or diabetics or pediatric) and no data on alcohol consumption or other liver diseases. Incidence of hepatocellular carcinoma (HCC), cirrhosis, overall mortality, and liver-related mortality were determined. NASH required histological diagnosis. All studies were reviewed by three independent investigators. Analysis was stratified by region, diagnostic technique, biopsy indication, and study population. We used random-effects models to provide point estimates (95% confidence interval [CI]) of prevalence, incidence, mortality and incidence rate ratios, and metaregression with subgroup analysis to account for heterogeneity. Of 729 studies, 86 were included with a sample size of 8,515,431 from 22 countries. Global prevalence of NAFLD is 25.24% (95% CI: 22.10-28.65) with highest prevalence in the Middle East and South America and lowest in Africa. Metabolic comorbidities associated with NAFLD included obesity (51.34%; 95% CI: 41.38-61.20), type 2 diabetes (22.51%; 95% CI: 17.92-27.89), hyperlipidemia (69.16%; 95% CI: 49.91-83.46%), hypertension (39.34%; 95% CI: 33.15-45.88), and metabolic syndrome (42.54%; 95% CI: 30.06-56.05). Fibrosis progression proportion, and mean annual rate of progression in NASH were 40.76% (95% CI: 34.69-47.13) and 0.09 (95% CI: 0.06-0.12). HCC incidence among NAFLD patients was 0.44 per 1,000 person-years (range, 0.29-0.66). Liver-specific mortality and overall mortality among NAFLD and NASH were 0.77 per 1,000 (range, 0.33-1.77) and 11.77 per 1,000 person-years (range, 7.10-19.53) and 15.44 per 1,000 (range, 11.72-20.34) and 25.56 per 1,000 person-years (range, 6.29-103.80). Incidence risk ratios for liver-specific and overall mortality for NAFLD were 1.94 (range, 1.28-2.92) and 1.05 (range, 0.70-1.56).
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

              Nonalcoholic fatty liver disease (NAFLD) is characterized by hepatic steatosis in the absence of a history of significant alcohol use or other known liver disease. Nonalcoholic steatohepatitis (NASH) is the progressive form of NAFLD. The Pathology Committee of the NASH Clinical Research Network designed and validated a histological feature scoring system that addresses the full spectrum of lesions of NAFLD and proposed a NAFLD activity score (NAS) for use in clinical trials. The scoring system comprised 14 histological features, 4 of which were evaluated semi-quantitatively: steatosis (0-3), lobular inflammation (0-2), hepatocellular ballooning (0-2), and fibrosis (0-4). Another nine features were recorded as present or absent. An anonymized study set of 50 cases (32 from adult hepatology services, 18 from pediatric hepatology services) was assembled, coded, and circulated. For the validation study, agreement on scoring and a diagnostic categorization ("NASH," "borderline," or "not NASH") were evaluated by using weighted kappa statistics. Inter-rater agreement on adult cases was: 0.84 for fibrosis, 0.79 for steatosis, 0.56 for injury, and 0.45 for lobular inflammation. Agreement on diagnostic category was 0.61. Using multiple logistic regression, five features were independently associated with the diagnosis of NASH in adult biopsies: steatosis (P = .009), hepatocellular ballooning (P = .0001), lobular inflammation (P = .0001), fibrosis (P = .0001), and the absence of lipogranulomas (P = .001). The proposed NAS is the unweighted sum of steatosis, lobular inflammation, and hepatocellular ballooning scores. In conclusion, we present a strong scoring system and NAS for NAFLD and NASH with reasonable inter-rater reproducibility that should be useful for studies of both adults and children with any degree of NAFLD. NAS of > or =5 correlated with a diagnosis of NASH, and biopsies with scores of less than 3 were diagnosed as "not NASH."
                Bookmark

                Author and article information

                Contributors
                Journal
                JCI Insight
                JCI Insight
                JCI Insight
                JCI Insight
                American Society for Clinical Investigation
                2379-3708
                10 January 2023
                10 January 2023
                10 January 2023
                : 8
                : 1
                : e153831
                Affiliations
                [1 ]Department for General, Visceral and Thoracic Surgery,
                [2 ]Institute of Medical Systems Biology, Center for Biomedical AI (bAIome), Center for Molecular Neurobiology (ZMNH),
                [3 ]I Department of Medicine,
                [4 ]Bioinformatics Core, and
                [5 ]III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
                [6 ]Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
                [7 ]Department of Pathology, Aarhus University Hospital, Aarhus, Denmark.
                [8 ]University’s Children Hospital, UKE Hamburg, Hamburg, Germany.
                [9 ]Department of Immunobiology, School of Medicine, Yale University, New Haven, Connecticut, USA.
                [10 ]Immunology and Allergy Unit, Department of Medicine, Solna, Karolinska Institute and University Hospital, Stockholm, Sweden.
                Author notes
                Address correspondence to: Nicola Gagliani, Martinistraße 52, 20246 Hamburg, Germany. Phone: 49.74.105.5406; Email: n.gagliani@ 123456uke.de .

                Authorship note: AW, PS, and YZ contributed equally to this work.

                Author information
                http://orcid.org/0000-0003-0577-0576
                http://orcid.org/0000-0002-3982-7019
                http://orcid.org/0000-0003-2632-7530
                http://orcid.org/0000-0001-5136-9922
                http://orcid.org/0000-0002-8624-1045
                http://orcid.org/0000-0003-0176-067X
                http://orcid.org/0000-0002-5898-2751
                http://orcid.org/0000-0003-1519-8104
                http://orcid.org/0000-0001-7674-1276
                http://orcid.org/0000-0002-2545-8160
                http://orcid.org/0000-0002-5070-874X
                http://orcid.org/0000-0002-0944-7226
                http://orcid.org/0000-0002-7735-5462
                http://orcid.org/0000-0001-7175-5062
                http://orcid.org/0000-0001-7262-9455
                http://orcid.org/0000-0003-4366-5662
                http://orcid.org/0000-0001-9325-8227
                http://orcid.org/0000-0001-8514-1395
                Article
                153831
                10.1172/jci.insight.153831
                9870087
                36625344
                f68c4103-2e99-421c-bd8c-5839f3b9768b
                © 2023 Woestemeier et al.

                This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 11 August 2021
                : 17 November 2022
                Funding
                Funded by: Deutsche Forschungsgemeinschaft, https://doi.org/10.13039/501100001659;
                Award ID: SFB841
                Funded by: European Research Council, https://doi.org/10.13039/501100000781;
                Award ID: 715271
                Categories
                Technical Advance

                hepatology,immunology,fibrosis,t cells
                hepatology, immunology, fibrosis, t cells

                Comments

                Comment on this article